Transcriptomics

Dataset Information

0

Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity III

ABSTRACT: Bulk RNA sequence (RNA-seq) has been used to explore the effect of IL10/CSF1R fusion protein modulation in tumor microenvironment. Four groups were analyzed which contain Ctrl, CSF1R, IL10 and BF10. MTC-Q1 oral cancer cells were orthotopic injection in C57BL/6 mice. CD45-negatve cells has been isolated and RNA were extracted by Trizol, followed by cDNA were sequenced by Illumina NextSeq 550.

ORGANISM(S): Mus musculus

PROVIDER: GSE193050 | GEO | 2023/07/09

REPOSITORIES: GEO

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

Transcriptomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity V
2023-07-09 | GSE193054 | GEO
Transcriptomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity
2023-07-09 | GSE190111 | GEO
Transcriptomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity IV
2023-07-09 | GSE193051 | GEO
Transcriptomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity II
2023-07-09 | GSE193045 | GEO
Genomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity
| PRJNA785881 | ENA
Genomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity III
| PRJNA794186 | ENA
Genomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity II
| PRJNA794177 | ENA
Genomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity IV
| PRJNA794187 | ENA
Genomics Interleukin-10/CSF1R fusion protein rejuvenates the exhausted T cells for executing antitumor activity V
| PRJNA794196 | ENA
Transcriptomics Single cell sequence of tumor infiltrated immune cells after cisplatin treatment in control or miR-21 KO in mouse oral cancer model
2022-08-29 | GSE172326 | GEO